{"protocolSection":{"identificationModule":{"nctId":"NCT00621946","orgStudyIdInfo":{"id":"092007-057"},"organization":{"fullName":"University of Texas Southwestern Medical Center","class":"OTHER"},"briefTitle":"Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder","officialTitle":"Escitalopram in the Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial"},"statusModule":{"statusVerifiedDate":"2014-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-03"},"primaryCompletionDateStruct":{"date":"2010-03","type":"ACTUAL"},"completionDateStruct":{"date":"2010-03","type":"ACTUAL"},"studyFirstSubmitDate":"2008-02-11","studyFirstSubmitQcDate":"2008-02-21","studyFirstPostDateStruct":{"date":"2008-02-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-05-24","resultsFirstSubmitQcDate":"2013-11-08","resultsFirstPostDateStruct":{"date":"2013-12-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-01-02","lastUpdatePostDateStruct":{"date":"2014-02-04","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Sherwood Brown","investigatorTitle":"Principal Investigator, MD/PhD","investigatorAffiliation":"University of Texas Southwestern Medical Center"},"leadSponsor":{"name":"University of Texas Southwestern Medical Center","class":"OTHER"},"collaborators":[{"name":"Forest Laboratories","class":"INDUSTRY"}]},"descriptionModule":{"briefSummary":"The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD). 2) Escitalopram treatment will be associated with greater improvement in asthma symptoms than placebo in outpatients with severe asthma and moderate or severe MDD. 3) Escitalopram treatment will be associated with greater depressive symptom remission rates than placebo in outpatients with severe asthma and moderate or severe MDD.","detailedDescription":"Primary Aim\n\n1\\) Determine if escitalopram treatment is associated with less oral corticosteroid use for asthma symptom control than placebo in asthma outpatients with moderate or MDD.\n\nSecondary Aims\n\n1. Determine if escitalopram treatment is associated with greater improvement in asthma symptoms than placebo in outpatients with severe asthma and moderate or severe MDD.\n2. Determine if escitalopram treatment is associated with greater depressive symptom remission rates than placebo in outpatients with severe asthma and moderate or severe MDD.\n\nBackground/Significance\n\nAsthma is a common, chronic general medical condition characterized by inflammation and variable, but usually reversible, airflow obstruction. Approximately 7.2% of people in the United States have a history of asthma. Asthma is common with an increasing prevalence and mortality especially in low-income and minority populations.\n\nThe course of asthma appears to be influenced by mood and emotions. It has been reported that there is a high prevalence of depression or depressive symptoms in both children and adults with asthma.\n\nDepression is associated with increased use of asthma-related urgent care services, as well as a variety of unfavorable asthma outcomes. In addition to the possible associations between depression and asthma medication nonadherence and even death, depression appears to be associated with increased use of emergency rooms, hospitals, and unscheduled appointments for asthma.\n\nDespite data on the frequency of depression in asthma and its adverse consequences, it is generally not recognized or treated.\n\nOur proposed study is different. We observed a modest difference between antidepressant and placebo in a prior trial. However, in a subgroup with more severe asthma (based on frequent corticosteroid use) and more severe depression (based on higher depressive symptoms scores) we saw a much larger effect size. The proposed study will target this subgroup. The sample size is based on the effect size we observed in this subgroup in our previous pilot study.\n\nA placebo controlled trial is needed because 1) the primary outcome in our previous trial was not significant. Therefore, it is not clear that antidepressant treatment is effective in depressed asthma patients. 2) We identified a subgroup with greater depressive symptom and asthma severity that based on a post-hoc analysis appeared to show a favorable response to the antidepressant. Thus, we want to confirm these post-hoc findings with a targeted prospective study. In the clinical population we will study, very few patients have ever received assessment or treatment for depression. Therefore, we would not be withholding clearly effective treatment that they would otherwise receive.\n\nStandard of care for severe asthma is aggressive asthma treatment. Our study does not require any changes in the patient's asthma treatment. No guidelines are currently available on the treatment of depression in asthma patients. Standard care for depression would be antidepressants."},"conditionsModule":{"conditions":["Severe Asthma","Moderate or Severe Major Depressive Disorder"],"keywords":["Asthma","Depression","Escitalopram"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":26,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo Matching Escitalopram given orally daily (for a 12-week duration).","interventionNames":["Drug: Placebo"]},{"label":"Escitalopram","type":"ACTIVE_COMPARATOR","description":"Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.","interventionNames":["Drug: Escitalopram"]}],"interventions":[{"type":"DRUG","name":"Placebo","description":"Placebo Matching Escitalopram","armGroupLabels":["Placebo"],"otherNames":["Placebo Matching Escitalopram"]},{"type":"DRUG","name":"Escitalopram","description":"Active Escitalopram","armGroupLabels":["Escitalopram"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"HAM-D (Hamilton Rating Scale for Depression)","description":"The HAM-D is a 17 item questionnaire (a clinician-administered depression scale) designed to evaluate severity of depressive symptoms. Scores can range from 0 to 52. The higher the score, the worse the depressive symptoms (worse outcome).","timeFrame":"Baseline"},{"measure":"ACQ (Asthma Control Questionnaire)","description":"The ACQ is a questionnaire used to assess symptoms pertinent to asthma management. Scores range from 0 to 42. The higher the score, the worse the asthma symptoms (worse outcome). The total ACQ score is obtained by dividing the raw score by the total number of items (in this case 7 items).","timeFrame":"Baseline"},{"measure":"IDS-SR (Inventory of Depressive Symptomatology - Self-Report)","description":"The IDS-SR is a 30 item (self-report questionnaire) designed to assess symptoms of depression. Scores range from 0 to 90. The higher the score, the worse the depressive symptoms (worse outcome).","timeFrame":"Baseline"},{"measure":"HAM-D (Hamilton Rating Scale for Depression)","description":"The HAM-D is a 17 item questionnaire (a clinician-administered depression scale) designed to evaluate severity of depressive symptoms. Scores can range from 0 to 52. The higher the score, the worse the depressive symptoms (worse outcome).","timeFrame":"Up to 12 weeks"},{"measure":"ACQ (Asthma Control Questionnaire)","description":"The ACQ is a questionnaire used to assess symptoms pertinent to asthma management.Scores range from 0 to 42. The higher the score, the worse the asthma symptoms (worse outcome). The total ACQ score is obtained by dividing the raw score by the total number of items (in this case 7 items).","timeFrame":"Up to 12 weeks"},{"measure":"IDS-SR (Inventory of Depressive Symptomatology - Self-Report)","description":"The IDS-SR is a 30 item (self-report questionnaire) designed to assess symptoms of depression. Scores range from 0 to 90. The higher the score, the worse the depressive symptoms (worse outcome).","timeFrame":"Up to 12 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Current HAM-D score of ≥ 20\n* Patients with severe asthma (defined as asthma requiring three or more course of oral corticosteroids in the past year).\n* No changes in asthma medications, oral corticosteroid use, or treatment for respiratory tract infections in the past week\n* Needs to have taken ≥ 3 courses of oral corticosteroids, for asthma, in the past 12 months.\n* Both male and female\n* English- or Spanish-speaking\n\nExclusion Criteria:\n\n* Current substance or alcohol abuse/dependence\n* MDD with psychotic features (delusions, hallucinations, disorganized thought processes)\n* Bipolar disorder\n* Schizophrenia or schizoaffective disorder\n* Substance-induced mood disorder and mood disorder secondary to a general medical condition\n* Mental retardation or other severe cognitive impairment\n* Prison or jail inmates\n* Pregnant or nursing women or women of childbearing age who will not use The University of Texas Southwestern Medical Center - Institutional Review Board (UTSW IRB) approved methods of birth control or abstinence during the study\n* Treatment-resistant depressed persons defined as having failed two adequate trials of antidepressants\n* Current antipsychotic or antidepressant therapy or psychotherapy\n* Initiation of other psychotropic medications or psychotherapy within past 2 weeks (e.g., anxiolytics, hypnotics)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"E. Sherwood Brown, Ph.D, M.D.","affiliation":"UT Southwestern Medical Center at Dallas","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"The UT Southwestern Medical Center at Dallas","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}}]},"referencesModule":{"references":[{"pmid":"37952772","type":"DERIVED","citation":"Agarwal CD, Palka JM, Gajewski AJ, Khan DA, Brown ES. The efficacy of citalopram or escitalopram in patients with asthma and major depressive disorder. Ann Allergy Asthma Immunol. 2024 Mar;132(3):374-382. doi: 10.1016/j.anai.2023.11.004. Epub 2023 Nov 11."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Escitalopram","description":"Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4."},{"id":"FG001","title":"Matching Placebo","description":"Placebo Matching Escitalopram taken orally daily (for a 12-week duration)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"One participant had no post-baseline data, leaving 25 evaluable participants in the intent-to-treat sample that was used in the analysis.","groups":[{"id":"BG000","title":"Escitalopram","description":"Active Escitalopram (A SSRI) taken orally in 10mg or 20mg doses daily."},{"id":"BG001","title":"Placebo","description":"Placebo Matching Escitalopram taken orally daily."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"25"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42.5","spread":"9.8"},{"groupId":"BG001","value":"48.6","spread":"12.7"},{"groupId":"BG002","value":"45.4","spread":"11.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"25"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"HAM-D (Hamilton Rating Scale for Depression)","description":"The HAM-D is a 17 item questionnaire (a clinician-administered depression scale) designed to evaluate severity of depressive symptoms. Scores can range from 0 to 52. The higher the score, the worse the depressive symptoms (worse outcome).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Escitalopram","description":"Active Escitalopram (A SSRI) taken orally in 10mg or 20mg doses daily."},{"id":"OG001","title":"Placebo","description":"Placebo Matching Escitalopram taken orally daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":"4.4"},{"groupId":"OG001","value":"28.3","spread":"5.1"}]}]}]},{"type":"PRIMARY","title":"ACQ (Asthma Control Questionnaire)","description":"The ACQ is a questionnaire used to assess symptoms pertinent to asthma management. Scores range from 0 to 42. The higher the score, the worse the asthma symptoms (worse outcome). The total ACQ score is obtained by dividing the raw score by the total number of items (in this case 7 items).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Escitalopram","description":"Active Escitalopram (A SSRI) taken orally in 10mg or 20mg doses daily."},{"id":"OG001","title":"Placebo","description":"Placebo Matching Escitalopram taken orally daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.1"},{"groupId":"OG001","value":"2.9","spread":"0.9"}]}]}]},{"type":"PRIMARY","title":"IDS-SR (Inventory of Depressive Symptomatology - Self-Report)","description":"The IDS-SR is a 30 item (self-report questionnaire) designed to assess symptoms of depression. Scores range from 0 to 90. The higher the score, the worse the depressive symptoms (worse outcome).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Escitalopram","description":"Active Escitalopram (A SSRI) taken orally in 10mg or 20mg doses daily."},{"id":"OG001","title":"Placebo","description":"Placebo Matching Escitalopram taken orally daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":"15.0"},{"groupId":"OG001","value":"42.9","spread":"12.3"}]}]}]},{"type":"PRIMARY","title":"HAM-D (Hamilton Rating Scale for Depression)","description":"The HAM-D is a 17 item questionnaire (a clinician-administered depression scale) designed to evaluate severity of depressive symptoms. Scores can range from 0 to 52. The higher the score, the worse the depressive symptoms (worse outcome).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Up to 12 weeks","groups":[{"id":"OG000","title":"Escitalopram","description":"Active Escitalopram (A SSRI) taken orally in 10mg or 20mg doses daily."},{"id":"OG001","title":"Matching Placebo","description":"Placebo Matching Escitalopram taken orally daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"11.4"},{"groupId":"OG001","value":"17.7","spread":"7.6"}]}]}]},{"type":"PRIMARY","title":"ACQ (Asthma Control Questionnaire)","description":"The ACQ is a questionnaire used to assess symptoms pertinent to asthma management.Scores range from 0 to 42. The higher the score, the worse the asthma symptoms (worse outcome). The total ACQ score is obtained by dividing the raw score by the total number of items (in this case 7 items).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Up to 12 weeks","groups":[{"id":"OG000","title":"Escitalopram","description":"Active Escitalopram (A SSRI) taken orally in 10mg or 20mg doses daily."},{"id":"OG001","title":"Matching Placebo","description":"Placebo Matching Escitalopram taken orally daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.4"},{"groupId":"OG001","value":"2.4","spread":"1.2"}]}]}]},{"type":"PRIMARY","title":"IDS-SR (Inventory of Depressive Symptomatology - Self-Report)","description":"The IDS-SR is a 30 item (self-report questionnaire) designed to assess symptoms of depression. Scores range from 0 to 90. The higher the score, the worse the depressive symptoms (worse outcome).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Up to 12 weeks","groups":[{"id":"OG000","title":"Escitalopram","description":"Active Escitalopram (A SSRI) taken orally in 10mg or 20mg doses daily."},{"id":"OG001","title":"Matching Placebo","description":"Placebo Matching Escitalopram taken orally daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":"17.4"},{"groupId":"OG001","value":"24.6","spread":"14.9"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","eventGroups":[{"id":"EG000","title":"Escitalopram","description":"Active Escitalopram (A SSRI) taken orally in 10mg or 20mg doses daily.","seriousNumAffected":2,"seriousNumAtRisk":13,"otherNumAffected":0,"otherNumAtRisk":13},{"id":"EG001","title":"Placebo","description":"Placebo Matching Escitalopram taken orally daily.","seriousNumAffected":1,"seriousNumAtRisk":12,"otherNumAffected":0,"otherNumAtRisk":12}],"seriousEvents":[{"term":"Severe asthma attack","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Participant experienced a severe asthma attack, lost consciousness and was intubated at the intensive care unit. This event was serious, expected due to the patient's history, and not study-related. The patient was discontinued from the study.","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Asthma exacerbation","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"This participant reported hospitalization for asthma exacerbation. This event was classified as serious, expected due to the patient's history, not study-related. The patient completed the study.","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Respiratory Infection","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"This participant was hospitalized for a worsening of asthma symptoms due to a viral respiratory infection that was successfully treated. This event was serious, unexpected, and not study-related. The patient was continued in the study.","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"A limitation of this proof-of-concept study was the small sample size."},"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"E. Sherwood Brown, MD, PhD","organization":"The University of Texas Southwestern Medical Center","email":"Sherwood.Brown@UTSouthwestern.edu","phone":"214-645-6950"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D001249","term":"Asthma"},{"id":"D008224","term":"Lymphoma, Follicular"},{"id":"D003865","term":"Depressive Disorder, Major"},{"id":"D003863","term":"Depression"}],"ancestors":[{"id":"D001982","term":"Bronchial Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D008173","term":"Lung Diseases, Obstructive"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012130","term":"Respiratory Hypersensitivity"},{"id":"D006969","term":"Hypersensitivity, Immediate"},{"id":"D006967","term":"Hypersensitivity"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D008223","term":"Lymphoma"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D001526","term":"Behavioral Symptoms"},{"id":"D001519","term":"Behavior"}]},"interventionBrowseModule":{"meshes":[{"id":"D000089983","term":"Escitalopram"}],"ancestors":[{"id":"D011437","term":"Propylamines"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D009570","term":"Nitriles"},{"id":"D001572","term":"Benzofurans"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}